XML 39 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Loss Before Income Tax - Additional Information (Details)
€ in Millions
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 12, 2018
USD ($)
Sep. 14, 2018
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2019
USD ($)
Oct. 31, 2019
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Jun. 21, 2019
EUR (€)
Disclosure Of Loss Before Income Tax Line Item                    
Pre-launch inventory recognized           $ 28,000,000.0   $ 28,900,000    
Provision for obsolete stock           300,000   500,000    
Manufacturing Commercialization Expenses                    
Disclosure Of Loss Before Income Tax Line Item                    
Pre-launch inventory recognized           900,000   $ 7,000,000.0    
Grunenthal                    
Disclosure Of Loss Before Income Tax Line Item                    
Non-refundable upfront payment received         $ 15,000,000.0          
Milestone payment received       $ 2,500,000            
Percentage of patients to provide regulatory harmonization, cost efficiencies and streamlined timelines     20.00%              
Non-refundable upfront payments receivable     $ 17,500,000              
Cumulative milestone payments reachable amount     1,000,000,000              
Revenue recognized relation to patent license agreement           0 $ 0      
Grunenthal | Clinical, Manufacturing, Regulatory and Reimbursement Approval | Top of Range                    
Disclosure Of Loss Before Income Tax Line Item                    
Non-refundable upfront payments receivable     $ 112,500,000              
Tasly                    
Disclosure Of Loss Before Income Tax Line Item                    
Deferred consideration up-front milestone receivable recognized $ 20,000,000.0         20,000,000.0        
Receipt on non refundable up-front payment upon reaching product regulatory milestone           25,000,000.0        
Revenue recognized from up-front payment as deferred consideration $ 10,000,000.0 $ 10,000,000.0       0 0      
TiGenix NV                    
Disclosure Of Loss Before Income Tax Line Item                    
Royalty income           100,000 100,000      
Milestone revenue in relation to patent license agreement           0 1,200,000      
Regulatory milestone payment receivable                 $ 1,000,000.0  
TiGenix NV | Top of Range                    
Disclosure Of Loss Before Income Tax Line Item                    
Milestone revenue relating to non-refundable up-front payment | €                   € 10.0
JCR Pharmaceuticals Co. Ltd                    
Disclosure Of Loss Before Income Tax Line Item                    
Royalties receivable under sales-based milestones           $ 1,400,000 $ 2,300,000